Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

That increase has boosted valuations, as the price-to-sales (P/S) ratio of 19 indicates that the stock is not cheap. Still, considering that ServiceNow's average P/S ratio over the last five years is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

The cousin of an FBI trainee who illegally obtained information about a planned Merck & Co acquisition from U.S. law firm ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...